Northern Treatment Advisory Group

Northern (NHS) Treatment Advisory Group

Teriparatide Biosimilar Uptake Recommendation

Date	8th December 2020
Appraisal & Details	Biosimilar teriparatide for the treatment of osteoporosis in postmenopausal women as per NICE TA161.
Recommendation	**The Northern (NHS) Treatment Advisory Group recommends the adoption of biosimilar teriparatide across the North Cumbria and North East Health Economy.** New patients should be offered biosimilar teriparatide as either Teriparatide Teva®, Terrosa® or Movymia®, and existing patients should continue to be prescribed Forsteo® until the end of the course. The biosimilar products are licensed for the same indications as the originator Forsteo®. All biological medicines, including biosimilar products, should be prescribed by brand.
Background	Teriparatide (Forsteo®, Eli Lilly) is a recombinant fragment of human parathyroid hormone which, as an anabolic agent, stimulates formation of new bone and increases resistance to fracture. It is administered daily as a subcutaneous injection for up to 24 months. The UK marketing authorisation includes treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture, and osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. In 2017 NICE approved use of teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161) Three biosimilar products of teriparatide have now received a UK marketing authorisation: • Movymia® ▼20 micrograms solution for injection (Thornton & Ross) • Terrosa® ▼ 20 microgram solution for injection (Gedeon Richter) • Teriparatide Teva 20 micrograms solution for injection (Teva UK Ltd) Due to lower acquisition costs of the biosimilars, there is an opportunity to reduce the per patient cost of teriparatide within the North East and North Cumbria. Teriparatide is commissioned either by the CCG or by NHSE dependent on the clinical indication. CCGs are the responsible commissioner for treatment of postmenopausal women with osteoporosis in line with NICE TA161. NHSE are the responsible commissioner where the treatment is for osteoporosis in men and children.

Northern Treatment Advisory Group

Northern (NHS) Treatment Advisory Group

Teriparatide Biosimilar Uptake Recommendation

Clinical evidence & Safety	All biosimilars introduced to the UK market are currently authorised by the European Medicines Agency (EMA) which evaluates biosimilars according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines approved in the EU.
Patient Perspective	The pharmaceutical form of two of the biosimilars varies from the originator. Forsteo® and Teriparatide Teva® are available as a pre-loaded disposable pen, whereas Movymia®▼ and Terrosa®▼ are supplied as cartridges. Starter packs are available with reusable pens that must be loaded with a cartridge each month. The use of biosimilar agents reduces the biologic drugs cost per patient, which in turn results in savings which can be reinvested into the local health economy.
Financial impact PbR: Tariff excluded	Teriparatide Brolucizumab is a CCG-commissioned a specified High Cost Drug (PBR-excluded).